Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kayla Haines

Nurse Practitioner Delray Beach, FL Nurse Practitioner

NPI 1598217499 CMS profile 11169403

5280 Linton Blvd, Delray Beach, FL 33484

Open in the dashboard

General payments

$15,686

546 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kayla Haines of Delray Beach, FL is reported in the CMS Open Payments database as having received $15,686 across 546 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $864 36
2024 General $3,727 158
2023 General $5,816 158
2022 General $1,699 61
2021 General $3,580 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kayla Haines
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kayla Haines were reported at $864. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kayla Haines Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $3,580 $135 $40–$426 $132
2022 $1,699 $152 $48–$470 $149
2023 $5,816 $166 $54–$529 $160
2024 $3,727 $173 $55–$556 $164
2025 $864 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $3,648 21 payments
  2. Merck Sharp & Dohme Corporation $1,126 50 payments
  3. AstraZeneca Pharmaceuticals LP $1,067 42 payments
  4. Novartis Pharmaceuticals Corporation $747 41 payments
  5. Janssen Biotech, Inc. $720 29 payments
  6. E.R. Squibb & Sons, L.L.C. $565 23 payments
  7. Pfizer Inc. $512 30 payments
  8. Seattle Genetics, Inc. $405 17 payments
  9. Celgene Corporation $397 20 payments
  10. Daiichi Sankyo Inc. $378 14 payments
  11. Other $6,121 259 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,764 527 payments
  2. Consulting Fee $3,430 3 payments
  3. Education $493 16 payments
Products named General payments · program years 2021–2025
  1. ALUNBRIG $2,296 6 payments
  2. KEYTRUDA $1,104 49 payments
  3. EXKIVITY $1,013 1 payment
  4. RYBREVANT $496 6 payments
  5. KRAZATI $438 17 payments
  6. OPDIVO $426 17 payments
  7. TAGRISSO $425 16 payments
  8. TUKYSA $389 19 payments
  9. KISQALI $381 22 payments
  10. ENHERTU $358 13 payments
  11. Other $10,763 504 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

184

Median for Nurse Practitioner: 389

Drug cost

$2,012

Median for Nurse Practitioner: $21,885

Branded share of claims

19%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Letrozole Generic 20 $519
Potassium Chloride Generic 20 $288
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 17 $250
Rosuvastatin Calcium Generic 23 $216
Prednisone Generic 31 $196
Tamoxifen Citrate Generic 18 $192
Ondansetron Odt Ondansetron Brand 18 $189
Levothyroxine Sodium Generic 26 $122
Azithromycin Generic 11 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$52,157

Of which drugs: $49,092

Medicare patients

50

Average age 80

Services billed

2,809

24 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 74%
Arthritis 60%
Ischemic heart disease 52%
Chronic kidney disease 40%
Osteoporosis 34%
Heart failure 30%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 13 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 68 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $278
$278 — —
ENHERTU
  • Daiichi Sankyo Inc. $216
  • AstraZeneca Pharmaceuticals LP $22
$238 — —
TAGRISSO
  • AstraZeneca Pharmaceuticals LP $224
$224 — —
KRAZATI
  • E.R. Squibb & Sons, L.L.C. $96
  • Mirati Therapeutics, Inc. $20
$116 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 68 with Patron

Records

546 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record